Business
Quarterly Update
Quarterly Update.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 3732A ValiRx PLC 07 June 2016 \n\n \n \n \n \nValiRx Plc\n(\"ValiRx\" or \"the Company\")\n \nQUARTERLY UPDATE ON CLINICAL DEVELOPMENTS \n\"Good progress on both Commercial and Scientific Fronts\"\n \nLondon, UK, 7th June 2016: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, provides a quarterly Q2 update on clinical progress.\n \n VAL201\nValiRx's lead compound, VAL201, continues to perform well in its Phase l/ll Clinical Trial in patients with hormone resistant prostate cancer and the Company was pleased to confirm in February 2016 that VAL201 is well tolerated and has shown a high degree of safety. To date, no drug related significant adverse events have been reported. Dose escalation has reached therapeutic levels and the studies have shown early indications of efficacy. The primary and secondary endpoints of the clinical trial have been further refined and confirmed and they continue to show no drug related adverse events.\nAdditional Clinical Trial Centers are being integrated into the study to assist with the dose expansion stage of the trial and this enlargement will expedite the production of data in order to complete the trial within the projected and regulatory-agreed time frame. ValiRx has also begun the process of designing the follow-up full efficacy study of VAL201 in prostate cancer. These will include a review of the most appropriate jurisdictions in which to undertake the work. This process and the development of the actual protocol, with costings and partnerships in place, is expected to be completed and in place by the time that the current Phase I/II trial reports.\nIn light of the excellent results shown by the compound and the promising pre-clinical evidence of the compound's effect on endometriosis, the Company is continuing the design of the protocol for this indication and to test VAL201 for its in-human potential in the treatment of this debilitating female condition. The protocol and associated partnerships - both commercial and technical - are expected to be in place before the final reporting of the current 'safety and tolerability-focused' clinical trial.\nFurthermore, the opportunity for developing and exploiting the compound for a furth...